• Vaccine Name: Inactivated whole MERS-CoV (IV) vaccine with CpG and Alum
• Target Pathogen: MERS-CoV
• Target Disease: Middle East Respiratory Syndrome (MERS)
• Type: Inactivated or "killed" vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: whole virus (Deng et al., 2018)
• Immunization Route: Intramuscular injection (i.m.)
• Description: inactivated whole MERS-CoV (IV) with a combined adjuvant (alum+CpG) as a vaccine formulation caused protection (Deng et al., 2018).

Mouse Response

• Host Strain: BALB/c
• Host gender: Female (Deng et al., 2018)
• Vaccination Protocol: intramuscularly injected with 1 μg IV protein adjuvant with 100 μL of alum and 10 μg of CpG at weeks 0, 4, and 8 (Deng et al., 2018)
• Immune Response: anti-S protein and anti-NP IgG response and neutralizing activity. (Deng et al., 2018)
• Challenge Protocol: 9 days of the last immunization, the remaining mice were lightly anesthetized with isoflurane and transduced intranasally with 2.5e8 plaque-forming units (pfu) of Ad5-hDPP443. After 5 days, transduced mice were infected intranasally with MERS-CoV (1e5 pfu) in 50 μL of DMEM (Deng et al., 2018)
• Efficacy: protected (Deng et al., 2018)